NCM
AMRX icon

Nantahala Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Nantahala Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.4M Buy
2,844,108
+396,592
+16% +$5.32M 1.3% 19
2025
Q4 		$30.8M Sell
2,447,516
-1,777,048
-42% -$20.3M 1.02% 23
2025
Q3 		$42.3M Sell
4,224,564
-142,874
-3% -$1.28M 1.47% 15
2025
Q2 		$35.3M Buy
4,367,438
+558,877
+15% +$4.21M 1.38% 12
2025
Q1 		$31.9M Buy
3,808,561
+143,032
+4% +$1.19M 1.27% 13
2024
Q4 		$29M Buy
3,665,529
+995,586
+37% +$8.35M 1.25% 15
2024
Q3 		$22.2M Hold
2,669,943
– – 1.12% 18
2024
Q2 		$17M Buy
2,669,943
+50,000
+2% +$317K 0.99% 19
2024
Q1 		$15.9M Buy
2,619,943
+285,546
+12% +$1.61M 0.91% 24
2023
Q4 		$14.2M Buy
2,334,397
+121,640
+5% +$542K 0.85% 23
2023
Q3 		$9.34M Buy
2,212,757
+63,452
+3% +$237K 0.8% 31
2023
Q2 		$6.66M Buy
2,149,305
+1,649,305
+330% +$3.51M 0.64% 40
2023
Q1 		$695K Buy
+500,000
New +$996K 0.05% 101

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Nantahala Capital Management's AMRX Position: Q1 2026 in Review

Nantahala Capital Management increased its Amneal Pharmaceuticals (AMRX) stake by 16% in Q1 2026, buying an estimated $5.32M and bringing the position to 2,844,108 shares worth $35.4M. The position accounts for 1.3% of the portfolio, ranked #19.

Nantahala Capital Management first reported a position in AMRX in Q1 2023 and has held it in 13 quarters since. The position peaked at $42.3M in Q3 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Nantahala Capital Management held 2,844,108 shares of Amneal Pharmaceuticals worth $35.4M as of Q1 2026.
  • Nantahala Capital Management bought 396,592 Amneal Pharmaceuticals shares in Q1 2026, an estimated $5.32M.
  • Amneal Pharmaceuticals made up 1.3% of Nantahala Capital Management's portfolio in Q1 2026, its #19 holding.
  • Nantahala Capital Management first reported a position in Amneal Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Nantahala Capital Management's Amneal Pharmaceuticals position peaked at $42.3M in Q3 2025.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.